

**Memo No.** 2021-002  
**Date:** 08-Feb-2021  
**Memo To:** Clients  
**Re:** *Various*

---

### **Revised Test Listing**

Complement C3 and C4 have revised specimen types and stability.

- [Complement C3, Serum](#)
  - [Complement C4, Serum](#)
- 

### **Upcoming Test Method Revision**

Effective 17 February 2021, the Galactomannan testing platform will change from the BioRad Evolis to the DSX. HL7 specifications will be provided once they are available from the testing lab

- [Galactomannan, Serum or Lavage](#)

#### **Change in Upper Level of Reporting**

Serum: 2.0 Index

Bronchoalveolar Lavage (BAL): 2.0 Index

Numeric Values will be reported up until an index of 2.0. Higher values will be reported as having an index of >2.0

#### **Additional Interpretative Comment**

This is a qualitative assay and values reported are not indicative of disease severity.

#### **Positivity Cut-off Remains**

The positivity cut-off will remain unchanged at .5

---

If you have further questions, please contact Client Care at (416) 422-3000 Ext. 300 or [info@ICLabs.ca](mailto:info@ICLabs.ca)

Dr. Shashank Tilak, Ph.D., DCC  
Laboratory Director  
(416) 422-3000 Ext. 221  
[ShashTilak@ICLabs.ca](mailto:ShashTilak@ICLabs.ca)

**Want to receive updates by e-mail? Please contact Client Care [info@ICLabs.ca](mailto:info@ICLabs.ca)**

*ICL is the only Not-For-Profit dedicated broker of lab diagnostic tests in Canada*

57 Gervais Drive, North York, ON M3C 1Z2

(416) 422-3000 Ext. 300 [info@ICLabs.ca](mailto:info@ICLabs.ca)